![]() |
Stephanie Fagan |
Stephanie Fagan, who did an eight-year stint at Johnson & Johnson and departed as VP-communications & PA, global medical solutions, has joined New York’s Mind Medicine Inc.
She takes the chief corporate affairs officer post at the New York-based clinical-stage biopharmaceutical company that strives to deliver on the therapeutical potential of psychedelics to treat brain health disorders.
In her more than 20 year career, Fagan held the CCO post at Agenus, SVP-corporate affairs & CCO at Acadia Pharmaceticals and SVP-corporate communications at Alexion.
Rob Barrow, CEO of MindMed, said Fagan’s "track record leading and executing successful multi-stakeholder strategies will be critial as we advance MM120 into pivotal trials and ultimately to the market.” In May, MindMed received a breakthrough therapy designation from the Food and Drug Administration for MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder.
In connection with her appointment, MindMed granted Fagan inducement awards consisting of (a) 60,000 time-based restricted stock units ("RSUs") and (b) an option to purchase an aggregate of 110,000 common shares of the Company (the "Option"), each with an effective grant date of July 29, 2024. The RSU’s vest over four years, and the option has an exercise price of $9.61, which was MindMed’s closing stock price on July 26.